{"nctId":"NCT01625377","briefTitle":"A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients","startDateStruct":{"date":"2012-12"},"conditions":["Liver Transplantation"],"count":188,"armGroups":[{"label":"Tacrolimus","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: tacrolimus","Drug: Basiliximab","Drug: Mycophenolic Acid","Drug: Corticosteroids"]},{"label":"Everolimus (RAD001)","type":"EXPERIMENTAL","interventionNames":["Drug: tacrolimus","Drug: everolimus","Drug: Basiliximab","Drug: Mycophenolic Acid","Drug: Corticosteroids"]}],"interventions":[{"name":"tacrolimus","otherNames":["Prograf®"]},{"name":"everolimus","otherNames":["Certican® / RAD001"]},{"name":"Basiliximab","otherNames":["Simulect®"]},{"name":"Mycophenolic Acid","otherNames":["Myfortic®"]},{"name":"Corticosteroids","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Man or woman aged 18 years or greater, recipient of a primary liver transplant from a deceased donor with whole or split liver\n\nKey Exclusion Criteria:\n\n* Patient recipient of multiple solid organ or islet cell tissue transplants, or have previously received an organ or tissue transplant\n* Recipient of a liver from a living donor or cadaveric non heart beating donor\n* ABO incompatible transplant graft\n* Transplantation following autoimmune liver hepatitis, primitive sclerosing cholangitis or primitive biliary cirrhosis\n* Estimated glomerular filtration rate ≤ 30ml/min at selection\n* History of malignancy within the 5 past years, other than non-metastatic basal or squamous cell carcinoma and hepatocellular carcinoma\n* Alpha-foeto-protein \\> 1000 ng/ml (only in case of hepatocellular carcinoma)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (Randomization) in Renal Function","description":"Change in renal function was measured by change in glomerular filtration rate (GFR). GFR calculated using the abbreviated modification of diet in renal disease (aMDRD) formula.\n\nGFR in mL/min/1.73m\\^2 for men of non-black ethnicity: 186 \\* \\[C/88\\]\\^-1.154 \\* \\[A\\]\\^-0.023\\*G\\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-13.29","spread":"2.75"},{"groupId":"OG001","value":"1.05","spread":"2.81"}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Treatment Failures","description":"Incidence of treatment failures, assessed with composite criterion including treated biopsy proven acute rejection (tBPAR) with a rejection activity index (RAI) according to Banff classification \\>3, graft loss or death at 6 months.\n\nBiopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.\n\nThe graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null},{"groupId":"OG001","value":"88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"9","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Treated or Not Treated Biopsy Proven Acute Rejection (BPAR)","description":"Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Reported With Different Categories of Severity of BPAR According to Banff Classification","description":"Biopsy proven acute rejection was defined as a clinically suspected acute rejection confirmed by biopsy.\n\nThe severity of BPAR was categorized as :\n\nMild (Banff grade I, RAI = 4 and 5) Moderate (Banff grade II, RAI = 6 and 7) Severe (Banff grade III, RAI = 8 and 9) Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Treated or Untreated BPAR With RAI Score Greater Than 3","description":"Biopsy proven acute rejection (BPAR) was defined as a clinically suspected acute rejection confirmed by biopsy. The Banff Rejection Activity Index (RAI) comprises 3 components scored from 0 to 3: venous endothelial inflammation; bile duct inflammation damage; and portal inflammation; the scores are combined to an overall score (the RAI) ranging from 0 to 9. An overall score of 0-3 is considered indeterminate, score of 4-5 is mild acute, score of 6-7 is moderate acute , and score of 8-9 is severe acute. Only the episode with the highest total RAI score for each participant was counted.\n\nThe patients with treated or untreated BPAR having RAI score \\> 3 were reported in this end point.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Death or Graft Loss","description":"The graft was presumed to be lost on the day the patient was registered again on the waiting list, or the day he/she received a new graft.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Randomization) in Serum Creatinine","description":"Change in serum creatinine concentrations from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function.\n\nBaseline was Day 28 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.2","spread":"36.0"},{"groupId":"OG001","value":"-1.3","spread":"38.53"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Randomization) in Urine Protein/Creatinine Ratio","description":"Change in urine protein/creatinine ratio from baseline (randomization) to week 24 post-randomization was one of the efficacy assessments of renal function. Baseline was Day 28 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.3","spread":"27.89"},{"groupId":"OG001","value":"21.9","spread":"92.00"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Randomization) in Creatinine Clearance Estimated Using the Adjusted Cockcroft-Gault Formula","description":"Creatinine clearance by the Cockcroft-Gault formula is computed in mL/min/1.73m\\^2 from the creatinine clearance in mL/min by multiplying it by 1.73 and dividing it by the body surface area Baseline was Day 28 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.0","spread":"30.63"},{"groupId":"OG001","value":"0.7","spread":"25.65"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by Abbreviated Modification of Diet in Renal Disease (MDRD) Formula","description":"Change in glomerular filtration rate was calculated using the MDRD abbreviated formula.\n\nGFR in mL/min/1.73m\\^2 for men of non-black ethnicity: 186 \\* \\[C/88\\]\\^-1.154 \\* \\[A\\]\\^-0.023\\*G\\*R ; C = serum creatinine (in μmol/L); A = Age (in years). G = 0.742 when the patient is a women; Otherwise G=1 R= 1.21 when the patient was of black ethnicity; Otherwise R = 1 Baseline was Day 28 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-11.8","spread":"34.01"},{"groupId":"OG001","value":"0.1","spread":"32.59"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline (Randomization) in Glomerular Filtration Rate Estimated by CKD-EPI Formula","description":"GFR estimated by using the Chronic kidney disease- epidemiology (CKD-EPI) formula:\n\neGFR (mL/min/1.73m\\^2) = 141 \\* min(C/K,1)\\^ α \\* max(C/K,1)\\^-1.209 \\* 0.993\\^A \\* 1.1018 (if male) \\* 1.159 (if black) where C = serum creatinine (in mg/dL) ; A = Age (in years); K = 0.7 for women and 0.9 for men; α = -0.329 for women and -0.411 for men. Baseline was Day 28 visit.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.9","spread":"20.11"},{"groupId":"OG001","value":"2.4","spread":"22.18"}]}]}]},{"type":"SECONDARY","title":"Number of Patients in Different Stages of Chronic Kidney Diseases According to the K/DOQI Classification System","description":"Kidney disease outcomes quality initiative (K/DOQI) classification is based on glomerular filtration rate (GFR), abbreviated MDRD formula (mL/min/1.73m\\^2) :\n\nStage 1 : GFR \\>= 90; Stage 2 = GFR was between 60-89; Stage 3 = GFR was between 30-59 ; Stage 4 = GFR was between 15-29; Stage 5 = GFR was \\< 15 (or dialysis)","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"24","spread":"27.89"},{"groupId":"OG001","value":"41","spread":"92.00"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients With Any Adverse Events, Serious Adverse Events, Death and Premature Discontinuation","description":"Baseline was Day 28 visit. This endpoint reports patients with total adverse events (any), serious adverse events, death and premature discontinuation.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85","spread":null},{"groupId":"OG001","value":"81","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28","spread":null},{"groupId":"OG001","value":"42","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"18","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":28,"n":94},"commonTop":["Cholestasis","Neutropenia","Diarrhoea","Hepatocellular injury","Anaemia"]}}}